Health-related quality of life in adults with drug-resistant focal epilepsy treated with modified Atkins diet in a randomized clinical trial.


Journal

Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R

Informations de publication

Date de publication:
05 2023
Historique:
revised: 10 03 2023
received: 16 11 2022
accepted: 13 03 2023
medline: 11 5 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Ketogenic diet, a high-fat, low-carbohydrate diet, is an established treatment for patients with severe epilepsy. We have previously reported a moderate reduction in seizure frequency after treatment with a modified Atkins diet. This study aimed to see whether dietary therapy impacts patients' health-related quality of life (HRQOL). In a randomized controlled design, we compared the change in self-reported HRQOL among adults with difficult-to-treat epilepsy after a 12-week diet intervention. Thirty-nine patients with drug-resistant focal epilepsy (age = 16-65 years) were randomized to eat a modified Atkins diet with maximum 16 g of carbohydrate per day (diet group, n = 19) or to continue eating habitual diet (control group, n = 20). No changes to the other epilepsy treatments were allowed. Patient-reported HRQOL was assessed with the Quality of Life in Epilepsy Inventory-89 (QOLIE-89). The diet group experienced a statistically significant improvement in mean total score of QOLIE-89 of 10 points compared to controls (p = .002). Moreover, although not statistically significant when using a cutoff of 50% seizure reduction, our data suggest an association between diet-induced reduction in seizure frequency and improvement in HRQOL. The improvement in HRQOL was not associated with diet-induced weight reduction.

Identifiants

pubmed: 36923995
doi: 10.1111/epi.17585
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e69-e74

Informations de copyright

© 2023 International League Against Epilepsy.

Références

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689-701.
Scott AJ, Sharpe L, Hunt C, Gandy M. Anxiety and depressive disorders in people with epilepsy: a meta-analysis. Epilepsia. 2017;58(6):973-82.
Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72(2):184-91.
Martin-McGill KJ, Jackson CF, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020;6:CD001903.
Lambrechts DA, Wielders LH, Aldenkamp AP, Kessels FG, de Kinderen RJ, Majoie MJ. The ketogenic diet as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav. 2012;23(3):310-4.
Shegelman A, Carson KA, McDonald TJW, Henry-Barron BJ, Diaz-Arias LA, Cervenka MC. The psychiatric effects of ketogenic diet therapy on adults with chronic epilepsy. Epilepsy Behav. 2021;117:107807.
Roehl K, Falco-Walter J, Ouyang B, Balabanov A. Modified ketogenic diets in adults with refractory epilepsy: efficacious improvements in seizure frequency, seizure severity, and quality of life. Epilepsy Behav. 2019;93:113-8.
van Berkel AA, Ijff DM, Verkuyl JM. Cognitive benefits of the ketogenic diet in patients with epilepsy: a systematic overview. Epilepsy Behav. 2018;87:69-77.
Devinsky O, Vickrey BG, Cramer J, Perrine K, Hermann B, Meador K, et al. Development of the quality of life in epilepsy inventory. Epilepsia. 1995;36(11):1089-104.
Stavem K, Bjornaes H, et al. Reliability and validity of a Norwegian version of the quality of life in epilepsy inventory (QOLIE-89). Epilepsia. 2000;41(1):91-7.
Kverneland M, Molteberg E, Iversen PO, Veierød MB, Taubøll E, Selmer KK, et al. Effect of modified Atkins diet in adults with drug-resistant focal epilepsy: a randomized clinical trial. Epilepsia. 2018;59(8):1567-76.
Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123-4.
Wiebe S, Matijevic S, Eliasziw M, Derry PA. Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry. 2002;73(2):116-20.
Ramm-Pettersen A, Stabell KE, Nakken KO, Selmer KK. Does ketogenic diet improve cognitive function in patients with GLUT1-DS? A 6- to 17-month follow-up study. Epilepsy Behav. 2014;39:111-5.
Langfitt JT, Vickrey BG, McDermott MP, Messing S, Berg AT, Spencer SS, et al. Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy. Qual Life Res. 2006;15(5):899-914.

Auteurs

Magnhild Kverneland (M)

National Center for Epilepsy, Member of the ERN EpiCARE, Oslo University Hospital, Oslo, Norway.

Karl Otto Nakken (KO)

National Center for Epilepsy, Member of the ERN EpiCARE, Oslo University Hospital, Oslo, Norway.

Dag Hofoss (D)

National Center for Epilepsy, Member of the ERN EpiCARE, Oslo University Hospital, Oslo, Norway.

Annette Holth Skogan (AH)

National Center for Epilepsy, Member of the ERN EpiCARE, Oslo University Hospital, Oslo, Norway.

Per Ole Iversen (PO)

Department of Nutrition, University of Oslo, Oslo, Norway.
Department of Hematology, Oslo University Hospital, Oslo, Norway.

Kaja Kristine Selmer (KK)

National Center for Epilepsy, Member of the ERN EpiCARE, Oslo University Hospital, Oslo, Norway.
Division of Clinical Neuroscience, Department of Research and Innovation, Oslo University Hospital, Oslo, Norway.

Morten Ingvar Lossius (MI)

National Center for Epilepsy, Member of the ERN EpiCARE, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH